Cargando…

Correction: Clinical characteristics, time course, treatment and outcomes of patients with immune checkpoint inhibitor-associated myocarditis

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2021
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8593697/ https://www.ncbi.nlm.nih.gov/pubmed/34782433 http://dx.doi.org/10.1136/jitc-2021-002553corr1

Ejemplares similares

Clinical characteristics, time course, treatment and outcomes of patients with immune checkpoint inhibitor-associated myocarditis
por: Puzanov, Igor, et al.
Publicado: (2021)

Clinical Characteristics and Outcomes in Immune Checkpoint Inhibitor Therapy-Associated Myocarditis
por: Thakker, Ravi A., et al.
Publicado: (2021)

Correction: (68)Ga-DOTATOC PET/CT to detect immune checkpoint inhibitor-related myocarditis
Publicado: (2022)

Correction to: Diagnostic Value of the International Society of Cardio‐Oncology Definition for Suspected Immune Checkpoint Inhibitor–Associated Myocarditis
Publicado: (2023)

Immune Checkpoint Inhibitor Myocarditis: Pathophysiological Characteristics, Diagnosis, and Treatment
por: Palaskas, Nicolas, et al.
Publicado: (2020)

Correction: Reversal of immune-checkpoint inhibitor fulminant myocarditis using personalized-dose-adjusted abatacept and ruxolitinib: proof of concept
Publicado: (2022)

Correction: Immune Checkpoint Inhibitor-Associated Colitis and Hepatitis
por: Reddy, Haritha G., et al.
Publicado: (2018)

Correction: Immune checkpoint inhibitor-associated celiac disease
Publicado: (2020)

Asymptomatic Immune Checkpoint Inhibitor-associated Myocarditis
por: Tanabe, Junya, et al.
Publicado: (2020)

Correction: Chronic immune checkpoint inhibitor pneumonitis
Publicado: (2020)

Varying presentations of immune checkpoint inhibitor-associated myocarditis: A case report of the clinical characteristics and outcomes of three patients
por: Fox, Brandon, et al.
Publicado: (2023)

Electrocardiographic features of immune checkpoint inhibitor associated myocarditis
por: Zlotoff, Daniel A, et al.
Publicado: (2021)

Combination immunomodulation for immune-checkpoint-inhibitor-associated myocarditis
por: Johnson, Douglas B., et al.
Publicado: (2023)

Correction: Efficacy of immune checkpoint inhibitors for in-transit melanoma
Publicado: (2020)

Correction: Defining unique clinical hallmarks for immune checkpoint inhibitor-based therapies
Publicado: (2022)

Immune Checkpoint Inhibitor Myocarditis Treatment Strategies and Future Directions
por: Moslehi, Javid, et al.
Publicado: (2022)

Pathophysiology of Immune Checkpoint Inhibitor-Induced Myocarditis
por: Jiménez-Alejandre, Rosa, et al.
Publicado: (2022)

Tocilizumab for refractory severe immune checkpoint inhibitor-associated myocarditis
por: Doms, J., et al.
Publicado: (2020)

Biomarker Trends, Incidence, and Outcomes of Immune Checkpoint Inhibitor–Induced Myocarditis
por: Vasbinder, Alexi, et al.
Publicado: (2022)

Correction: Acute kidney injury in patients treated with immune checkpoint inhibitors
Publicado: (2023)

Plasma Exchange for Immune Checkpoint Inhibitor–Induced Myocarditis
por: Yogasundaram, Haran, et al.
Publicado: (2020)

Drug therapy for myocarditis induced by immune checkpoint inhibitors
por: Wu, Yihao, et al.
Publicado: (2023)

Correction to: Impact of antibiotic therapy on the development and response to treatment of immune checkpoint inhibitor-mediated diarrhea and colitis
por: Abu-Sbeih, Hamzah, et al.
Publicado: (2019)

Myocarditis associated with immune checkpoint inhibitors: Practical considerations in diagnosis and management
por: Gürdoğan, Muhammet, et al.
Publicado: (2020)

Immune Checkpoint Inhibitor Associated Myocarditis and Cardiomyopathy: A Translational Review
por: Wang, Dong, et al.
Publicado: (2023)

Correction: Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors
Publicado: (2021)

COVID-19 VERSUS IMMUNE CHECKPOINT INHIBITOR MYOCARDITIS: A CLINICAL DILEMMA
por: Dewaswala, Nakeya, et al.
Publicado: (2023)

Immune Checkpoint Inhibitors-Related Myocarditis: A Review of Reported Clinical Cases
por: Zotova, Liudmila
Publicado: (2023)

A Case of Immune Checkpoint Inhibitor-Induced Probable Myocarditis and Treatment Response
por: Hassan, Mubariz A, et al.
Publicado: (2023)

Publisher Correction: Smac mimetics synergize with immune checkpoint inhibitors to promote tumour immunity against glioblastoma
por: Beug, Shawn T., et al.
Publicado: (2018)

Correction: On the use of immune checkpoint inhibitors in patients with viral infections including COVID-19
Publicado: (2021)

Immune checkpoint inhibitor–mediated myocarditis and ventricular tachycardia storm
por: McDowall, Lachlan M., et al.
Publicado: (2019)

Immune-Checkpoint Inhibitor-Induced Fulminant Myocarditis and Cardiogenic Shock
por: Itzhaki Ben Zadok, Osnat, et al.
Publicado: (2019)

Myocarditis Induced by Immune Checkpoint Inhibitors: Mechanisms and Therapeutic Prospects
por: Zou, Wenlu, et al.
Publicado: (2021)

Biomarkers for Immune Checkpoint Inhibitor–Induced Myocarditis: Caution Needed
por: Jaffe, Allan S.
Publicado: (2022)

Role of mitochondrial metabolism in immune checkpoint inhibitors-related myocarditis
por: Zhang, Xin, et al.
Publicado: (2023)

Immune checkpoint inhibitor–associated myocarditis: Case reports and a review of the literature
por: Osinga, T. E., et al.
Publicado: (2022)

Sinus Node Dysfunction Co-occurring with Immune Checkpoint Inhibitor-associated Myocarditis
por: Nishikawa, Tatsuya, et al.
Publicado: (2022)

Immune checkpoint inhibitor–associated myocarditis: a systematic analysis of case reports
por: Wang, Caie, et al.
Publicado: (2023)

TNF-α Inhibitors and Other Biologic Agents for the Treatment of Immune Checkpoint Inhibitor-Induced Myocarditis
por: Liu, Xiaohang, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_a7mv0vvmq52ubbvhepi99oqsaj